353 related articles for article (PubMed ID: 24425689)
1. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
Jabbour E; Ottmann OG; Deininger M; Hochhaus A
Haematologica; 2014 Jan; 99(1):7-18. PubMed ID: 24425689
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
Barrett D; Brown VI; Grupp SA; Teachey DT
Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Mughal TI; Girnius S; Rosen ST; Kumar S; Wiestner A; Abdel-Wahab O; Kiladjian JJ; Wilson WH; Van Etten RA
Leuk Lymphoma; 2014 Sep; 55(9):1968-79. PubMed ID: 24206094
[TBL] [Abstract][Full Text] [Related]
4. Phosphoinositide 3-kinase inhibitors in lymphoma.
Curran E; Smith SM
Curr Opin Oncol; 2014 Sep; 26(5):469-75. PubMed ID: 25024054
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.
Witzig TE; Kaufmann SH
Curr Treat Options Oncol; 2006 Jul; 7(4):285-94. PubMed ID: 16916489
[TBL] [Abstract][Full Text] [Related]
6. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
[TBL] [Abstract][Full Text] [Related]
7. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
Lauring J; Park BH; Wolff AC
J Natl Compr Canc Netw; 2013 Jun; 11(6):670-8. PubMed ID: 23744866
[TBL] [Abstract][Full Text] [Related]
8. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.
Dienstmann R; Rodon J; Serra V; Tabernero J
Mol Cancer Ther; 2014 May; 13(5):1021-31. PubMed ID: 24748656
[TBL] [Abstract][Full Text] [Related]
9. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.
Nefedova Y; Gabrilovich D
Drug Resist Updat; 2008 Dec; 11(6):210-8. PubMed ID: 18951834
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas.
Martín-Sánchez E; Rodríguez-Pinilla SM; Sánchez-Beato M; Lombardía L; Domínguez-González B; Romero D; Odqvist L; García-Sanz P; Wozniak MB; Kurz G; Blanco-Aparicio C; Mollejo M; Alves FJ; Menárguez J; González-Palacios F; Rodríguez-Peralto JL; Ortiz-Romero PL; García JF; Bischoff JR; Piris MA
Haematologica; 2013 Jan; 98(1):57-64. PubMed ID: 22801959
[TBL] [Abstract][Full Text] [Related]
12. Targeting the phosphoinositide 3-kinase pathway in cancer.
Liu P; Cheng H; Roberts TM; Zhao JJ
Nat Rev Drug Discov; 2009 Aug; 8(8):627-44. PubMed ID: 19644473
[TBL] [Abstract][Full Text] [Related]
13. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.
Klempner SJ; Myers AP; Cantley LC
Cancer Discov; 2013 Dec; 3(12):1345-54. PubMed ID: 24265156
[TBL] [Abstract][Full Text] [Related]
14. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.
Pavlidou A; Vlahos NF
ScientificWorldJournal; 2014; 2014():709736. PubMed ID: 24526917
[TBL] [Abstract][Full Text] [Related]
15. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
16. Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
Elmenier FM; Lasheen DS; Abouzid KAM
Eur J Med Chem; 2019 Dec; 183():111718. PubMed ID: 31581005
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
[TBL] [Abstract][Full Text] [Related]
18. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/AKT Pathway as a Target for Cancer Treatment.
Mayer IA; Arteaga CL
Annu Rev Med; 2016; 67():11-28. PubMed ID: 26473415
[TBL] [Abstract][Full Text] [Related]
20. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
